Quantitative MRI Tumor Forecasting With Reaction-Diffusion Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neoadjuvant therapy for cancer patients is not optimized for individual patient characteristics, relying on receptor status, tumor grade, and genetic markers, leading to ineffective treatment plans and significant side-effects due to a lack of mathematical models guiding therapeutic decisions.
Innovation Solution
A protocol using quantitative MRI data and biophysical, reaction-diffusion modeling to predict tumor response, incorporating DCE-MRI and DW-MRI for tissue properties, drug distribution, and tumor growth characteristics, enabling patient-specific treatment optimization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional therapy selection based on receptor status and tumor grade is used, then treatment protocols are simplified, but treatment effectiveness and patient-specific optimization are reduced
Solution Approach 1:
The patent transforms conventional binary treatment selection into a continuous optimization problem by introducing quantitative MRI parameters (cellularity, vascular density, perfusion) that continuously vary across tumor regions. This allows treatment parameters to be continuously adjusted based on measured tumor characteristics rather than fixed categorical selections, resolving the contradiction between protocol simplicity and treatment effectiveness.
Solution Approach 2:
The patent replaces the mechanical/requires manual selection process of conventional treatment protocols with an automated mathematical optimization system. The biophysical model automatically calculates optimal treatment parameters by minimizing an objective function that incorporates tumor response predictions and patient outcomes, eliminating the need for manual trial-and-error selection while improving treatment effectiveness.
2Reliability
If mathematical models are introduced to predict tumor response, then treatment optimization is improved, but model complexity and computational requirements increase
Solution Approach 1:
The patent segments the complex tumor biology into distinct quantifiable parameters (cellularity, vascular density, perfusion, interstitial fluid pressure) that can be independently measured by MRI and incorporated into the biophysical model. This segmentation allows the complex tumor response prediction to be broken down into manageable components, reducing overall model complexity while maintaining prediction accuracy.
Solution Approach 2:
The patent introduces quantitative MRI measurements as an intermediary between the complex biological processes and the treatment optimization algorithm. The MRI parameters serve as measurable proxies for underlying biological states, allowing the mathematical model to predict treatment response without directly simulating complex cellular interactions, thus reducing computational complexity while maintaining accuracy.
3Measurement precision
If patient-specific calibration is performed, then prediction accuracy for individual patients is improved, but processing time and computational resources increase
Solution Approach 1:
The patent performs preliminary calibration by measuring tumor parameters at baseline before treatment initiation. The biophysical model is calibrated using pre-treatment MRI data to establish patient-specific tumor characteristics, allowing rapid prediction of treatment response without requiring continuous recalibration during treatment. This preliminary action reduces processing time during subsequent treatment phases while maintaining high prediction accuracy.
Data Source
AI summary
Disclosed are approaches to data acquisition, analysis, and computational forecasting that employs quantitative MRI data to predict the response of cancer to therapy. Example protocols detail how to acquire needed images followed by registration, segmentation, quantitative perfusion and diffusion analysis, model calibration, and prediction. The response of individual cancer patients to therapy is forecast by application of a biophysical, reaction-diffusion model to these data. Application of the protocol results in coregistered MRI data from at least two scan visits that quantifies an individual tumor's size, cellularity and vascular properties. This enables a spatially resolved prediction of how a particular patient's tumor will respond to therapy. A modified therapy can be determined based on predicted response.